What are Revlimid and Pomalyst?
Revlimid and Pomalyst are both oral prescription medicines used for multiple myeloma, but they contain different active ingredients and are used in different clinical settings.
Active ingredient: what’s the main difference?
- Revlimid contains lenalidomide.
- Pomalyst contains pomalidomide.
These drugs are closely related “immunomodulatory” (IMiD) agents used in myeloma, but pomalidomide is the later-generation option.
How do they differ in who they’re for (treatment lines)?
In practice, the difference is often tied to disease status and prior therapy:
- Revlimid (lenalidomide) is commonly used earlier in treatment sequences for multiple myeloma.
- Pomalyst (pomalidomide) is typically used for patients whose disease has returned or who no longer respond to prior therapies, including lenalidomide-based regimens.
Are they used with other medicines?
Both drugs are commonly paired with other therapies in myeloma regimens, but the exact combinations depend on the patient and treatment line. Your oncology team chooses the regimen based on prior treatments, risk factors, and tolerability.
Side effects: are they the same?
They overlap because they are in the same drug class, but the risk profile can differ patient-to-patient. Common concerns for both include:
- Low blood counts (for example, neutropenia or thrombocytopenia)
- Fatigue and other constitutional symptoms
- Risk of blood clots (and the need for clot-prevention strategies in many patients)
- GI symptoms (such as constipation or nausea)
Are there differences in monitoring or precautions?
Yes, because myeloma patients can have different baselines and because these agents can affect blood counts and clot risk. In general, patients on either medication require regular lab monitoring and adherence to safety precautions set by their prescribing oncologist.
Quick comparison (plain-language)
- Revlimid = lenalidomide, usually used earlier in multiple myeloma treatment.
- Pomalyst = pomalidomide, often used for relapsed/refractory disease, especially after prior lenalidomide treatment.
If you tell me whether you’re asking for use in a specific situation (new diagnosis vs relapsed/refractory) and what prior drugs you’ve had, I can explain how clinicians typically pick Revlimid vs Pomalyst for that scenario.
Sources
No sources were provided in the prompt. If you want, share the materials you’re using (or the DrugPatentWatch.com pages you’re looking at), and I can align the answer to those exact references.